Cosentyx™ (secukinumab) is recommended for approval as first-line systemic* therapy for the treatment of moderate-to-severe plaque psoriasis in adult patients, and is a first-in-class therapy that blocks the protein IL-17A, which is found in high concentrations in psoriasis affected skin1,2
Secukinumab has demonstrated greater efficacy in reducing plaque psoriasis than seen with an existing NICE-recommended treatment1
NICE recognises psoriasis is 'more than just a skin condition', affecting psychological and social wellbeing, and being associated with complex co-morbidities,including arthritis, diabetes and hypertension3–6
*Systemic: treatments or medication travel through the blood stream, allowing them to be carried where they are needed to work
1. Langley, R. G. et al. Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials. N. Engl. J. Med. 371, 326–38 (2014).
2. Johansen, C. et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br. J. Dermatol. 160, 319–324 (2009).
3. Takeshita, J. et al. Effect of Psoriasis Severity on Hypertension Control: A Population-Based Study in the United Kingdom. JAMA dermatology 19104, (2014).
4. Farley, E. & Menter, A. Psoriasis: comorbidities and associations. G. Ital. Dermatol. Venereol. 146, 9–15 (2011).
5. Gisondi, P. & Girolomoni, G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin. Thromb. Hemost. 35, 313–324 (2009).
6. NICE. Psoriasis is “more than just a skin condition.” (2014). at Accessed: November 2014